Overview

Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yonsei University
Treatments:
Insulin
Insulin, Globin Zinc
Pioglitazone
Criteria
Inclusion Criteria:

- Renal allograft recipients were eligible to participate in the study if they were aged
≥ 18 years, had no previous history of organ transplantation and were not currently
using steroids or other immunosuppressants.

Exclusion Criteria:

- Diabetes before transplantation

- Severe metabolic or infectious disease

- Hepatic disease

- Congestive heart failure (New York Heart Association II-IV)

- Cadaver donor kidney donor transplantation

- Unstable condition of the transplanted kidney